Objective:

To describe the evolution of the hair-loss clinical trial landscape from 2015 to 2025, focusing on trial volume, geography, indications, intervention types, outcome assessment, and sponsorship.

Approach:

Key Findings:

• 514 hair-loss trials identified, with registrations increasing over time, especially after 2020.
• Trial activity was global but concentrated in North America.
• Androgenetic alopecia and alopecia areata were the predominant conditions studied.
• Pharmacologic therapies were the most common interventions, with a variety of approaches noted in androgenetic alopecia.
• Outcome reporting was heterogeneous, and objective imaging was infrequent.

Interpretation:

The analysis highlights a rapidly expanding yet uneven landscape of hair-loss clinical research, marked by geographic concentration and variability in outcome specification.

Limitations:

• The study does not address the quality or effectiveness of the interventions.
• Outcome reporting was heterogeneous, complicating comparisons across studies.
• Certain populations were underrepresented in the trials.

Conclusion:

The findings indicate a need for standardized outcomes, broader population representation, and alignment between research investment and clinical need in hair-loss disorders.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.